Department of Communication Disorders, Boston University, Boston, USA.
Acta Neurol Scand. 2010 Mar;121(3):186-93. doi: 10.1111/j.1600-0404.2009.01160.x. Epub 2009 Sep 24.
To explore the longitudinal stability of measures of cognition during treatment with acetylcholinesterase inhibitors (AchEI) in patients with Alzheimer's disease (AD).
Cognitive status was measured in a cohort of 60 patients at 6 months after initiation of treatment with AchEI (baseline) and after an additional 6 months of treatment (endpoint). A Quick Test of Cognitive Speed (AQT), Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), and MMSE were administered concurrently.
Correlations (rho) between age and AQT processing speed were non-significant, but were significant for ADAS-Cog and Mini Mental State Examination (MMSE). AQT and ADAS-Cog means did not differ significantly between baseline and endpoint. There was a small, significant reduction in MMSE point scores. Measures of stability (Spearman's rho) were moderate-to-high for all tests. Means for subgroups did not differ as a function of medication type.
AQT processing speed, ADAS-Cog, and MMSE measures proved stable during the second 6 months of treatment with AChEI.
探索在阿尔茨海默病（AD）患者接受乙酰胆碱酯酶抑制剂（AchEI）治疗期间，认知测量的纵向稳定性。
在接受 AchEI 治疗 6 个月后（基线）和另外 6 个月的治疗后（终点），对 60 例患者的队列进行认知状态测量。同时进行快速认知速度测试（AQT）、阿尔茨海默病评估量表认知子量表（ADAS-Cog）和 MMSE 测试。
年龄与 AQT 处理速度之间的相关性（rho）不显著，但与 ADAS-Cog 和 Mini Mental State Examination（MMSE）显著相关。AQT 和 ADAS-Cog 的平均值在基线和终点之间没有显著差异。MMSE 的分数略有显著降低。所有测试的稳定性测量（Spearman rho）均为中至高。亚组的平均值不因药物类型而异。
在接受 AchEI 治疗的第二个 6 个月期间，AQT 处理速度、ADAS-Cog 和 MMSE 测量结果稳定。
